About
PamBio is a biotechnology company developing drug therapy for hemorrhagic stroke (e.g. intracranial bleeding and ICH) and other acute bleeding conditions. PamBio's solution for ICH drug treatment is an inactive recombinant mutant-tPA protein. Its S481A amino-acid substitution renders the protein catalytically inactive but maintains its structure and ability to interact with major components of the fibrinolytic pathway. In essence, the mutant-tPA drug molecule is a competitive inhibitor to the native-tPA. This therapeutic biomolecule has a dual antifibrinolytic and neuroprotective effect. It blocks both tPA and uPA fibrinolysis enzyme activity, enabling treatment beyond three hours, and it limits tPA and glutamate-mediated neurotoxicity by blocking the binding of the neurotoxic tPA to NMDA receptors, thus providing neuroprotection. PamBio is an NGT3 VC portfolio company.